Action BPMC BLUEPRINT MEDICINES CORPORATION
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués Blueprint Medicines Corporation

Actions

BPMC

US09627Y1091

Temps réel estimé Cboe BZX
Autres places de cotation
 21:39:19 16/07/2024 		Varia. 5j. Varia. 1 janv.
120,4 USD +0,71 % Graphique intraday de Blueprint Medicines Corporation +4,77 % +30,91 %
03/07 Annonce volontaire - CStone Pharmaceuticals et Jiangsu Hengrui Pharmaceuticals Co., Ltd concluent un accord de promotion exclusive d'AYVAKIT® (comprimés d'avapritinib) en Chine continentale CI
25/06 Un initié de Blueprint Medicines a vendu des actions pour une valeur de 7 713 537 $, selon un récent dépôt auprès de la SEC MT

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
CStone and Hengrui Enter into an Exclusive Promotion Agreement of AYVAKIT in Mainland China
AQ
BLUEPRINT MEDICINES : 2024 STOCK INCENTIVE PLAN Form 8 K
PU
Blueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT®/AYVAKYT® (avapritinib)
PR
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR
Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT/AYVAKYT Full Year Revenue Guidance
AQ
Blueprint Medicines: Q1 Earnings Snapshot
AQ
Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024
PR
Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics
PR
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR
Blueprint Medicines Highlights AYVAKIT Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting
AQ
Blueprint Medicines: Q4 Earnings Snapshot
AQ
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR
Blueprint Medicines to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 15, 2024
PR
Blueprint Medicines Highlights 2024 Corporate Strategy and Business Priorities at 42nd Annual J.P. Morgan Healthcare Conference
PR
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR
Blueprint Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference
PR
EC approves treatment for rare haematological disorder
AQ
Blueprint Medicines' AYVAKYT® (avapritinib) Receives European Commission Approval as the First and Only Treatment for Indolent Systemic Mastocytosis
PR
EUCOPE Member Spotlight, Q&A with Blueprint Medicines
AQ
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action BPMC
  4. Actualités Blueprint Medicines Corporation
  5. Communiqués